AI could predict who benefits from esophageal cancer therapy
NCT ID NCT07063901
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 21 times
Summary
This study uses artificial intelligence to analyze patient data—like scans, lab results, and medical history—to predict how well esophageal cancer responds to chemotherapy and immunotherapy before surgery. Researchers aim to identify which patients achieve a complete response and which do not, helping doctors tailor treatments. The study involves 200 adults with locally advanced esophageal cancer who are receiving standard neoadjuvant therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGUS CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Xiangya Hospital of Central South University
RECRUITINGChangsha, Hunan, 410011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.